Board of Directors

Drawing on a track record of entrepreneurial success, Jeff spearheaded multiple ventures, including a Canadian biotech that went from startup to IPO, raising $30M in 9 months. He has guided numerous private companies to public listings, generating over $100M in combined private and public market financing, with deep expertise in IPOs and M&A. Recognized among Canada’s Top 40 Under 40 for his leadership at his own national start-up. As an active investor and advisor, Jeff remains focused on public-market biotech, guiding emerging companies to accelerate growth and achieve successful exits.

Miles Harrison is a healthcare and aesthetics executive with a proven record of scaling global businesses, driving innovation, and creating shareholder value.

He currently serves on the Board of Castle Biosciences (NASDAQ: CSTL), and sits on the Compensation Committee and Nominating and Governance Committee, Castle Biosciences provides test solutions for the diagnosis and treatment of dermatologic cancers. Previously, Miles co-founded and led Novaestiq Corp., building a novel aesthetics platform, raising multi-millions in early financing, and securing strategic distribution with Croma Pharma in North America. He successfully positioned Novaestiq for a significant strategic exit in 2025.

Before Novaestiq, Miles was President & General Manager, North America at Galderma, leading three business units—Aesthetics, Consumer, and Prescription—across North America, with an expansive employee base and over $1.2B in revenue. He drove sustained growth and margin expansion, and scaled several iconic consumer, aesthetic and prescription brands including Cetaphil®, Differin®, Dysport®, Sculptra®, Restylane® and Epiduo®. Miles was part of the executive leadership team that supported EQT’s multi billion dollar acquisition of Galderma in late 2019.

Earlier, at Nestlé Skin Health, he built the U.S. Consumer Business Unit from the ground up, delivering double-digit organic growth and leading the first FDA-approved RX-to-OTC acne switch in 30 years (Differin® Gel).

Miles seeks to bring a blend of boardroom discipline and entrepreneurial drive to his next role as CEO of Conexeu™ Sciences Inc. Known for building high-performing teams and shaping cultures that thrive under change, he combines governance depth, capital strategy expertise, and hands-on operating leadership. At Conexeu™, he will lead the charge to bring first-in-class disruptive human collagen technologies to market across aesthetics, wound care, and regenerative medicine—pioneering a category that sits at the intersection of science, patient impact, and long-term value creation.

Dave is an entrepreneur and capital market professional. Including a Canadian biotech that went from startup to IPO, raising $30M in 9 months. Serves as an advisor on M&A and private capital transactions, delivering market assessments and benchmarking. Advised on numerous private and public transactions on the CSE, NEO, OTC, TSX.v and NASDAQ, including reverse mergers and IPOs. Working in the start-up and small-cap sectors, managing integrated investor relations, public relations campaigns in the US, Canada and E.U.

Aaron S. Farberg, M.D. is a double board-certified dermatologist and fellowship-trained Mohs surgeon that specializes in skin cancer, inflammatory diseases, and cosmetic dermatology. Dr. Farberg is a summa cum laude graduate of Emory University and continued his education at the University of Michigan where he received his medical degree. Dr. Farberg’s post-graduate training includes additional residency years at the University of Michigan in Plastic and Reconstructive Surgery and, in New York, as a clinical research fellow in association with the National Society for Cutaneous Medicine and New York University. He then remained in New York, completing another residency in Dermatology at the Icahn School of Medicine at Mount Sinai Hospital where he served as chief resident.

Dr. Farberg is the founder of a large group private practice in Dallas, Texas. He is also an Assistant Professor at the UNT Health Science Center where he is the Assistant Program Director for a Dermatology residency training program. In addition to treating patients, Dr. Farberg has been a clinical investigator on numerous studies including FDA clinical trials. He is an accomplished author and has published over 100 articles in professional medical journals. He serves as a member of the editorial board for several medical journals including Dermatology & Therapy and SKIN. Dr. Farberg also founded the Dermatology Science and Research Foundation to provide dermatology education to his patients and peers. Dr. Farberg has been recognized as one of Dallas’s leading dermatologists with numerous awards and honors. He most recently was ranked by his dermatology colleagues in Newsweek Magazine as the #1 medical dermatologist in Texas and #5 in the entire country. Dr. Farberg has 103 Publications, 76 Abstracts, 7 books (1 being completed).

Dr. Z. Paul Lorenc is a board-certified aesthetic plastic surgeon internationally recognized for pioneering advancements in minimally invasive aesthetic medicine. Renowned for his research on dermal fillers and injectables, he played a pivotal role in the Evolence® collagen filler study – a key clinical trial that supported Johnson & Johnson’s $159 million acquisition of Evolence. With a practice in New York City, Dr. Lorenc has authored numerous peer-reviewed articles and textbooks on aesthetic plastic surgery and has lectured extensively on emerging technologies and best practices in facial rejuvenation.

In addition to his clinical work, Dr. Lorenc serves on advisory boards and scientific panels, guiding innovations in collagen-based implants, neurotoxins, and energy-based devices. His deep understanding of clinical trial design and regulatory navigation allows him to effectively translate cutting-edge research into safe, effective treatments for patients seeking natural, long-lasting results. Dr. Lorenc’s philosophy centers on patient safety, rigorous scientific validation, and a commitment to enhancing quality of life through aesthetic solutions. At Conexeu, he provides strategic input on product development, clinical validation, and market positioning for the 10 Minute Tissue™ scaffold, ensuring it aligns with the evolving demands of a global aesthetic market.

Sebastian Purcell, Ph.D. is the Chief Executive Officer and Chief Investment Officer of 1.2 Capital, an alternative investment management firm spanning digital assets, venture, and macro strategies. His academic research bridges ethics and mathematical logic, with publications in areas including transfinite mathematics, paraconsistent logics, complex systems theory, environmental ethics, and Aztec philosophy.

Dr. Purcell earned his Ph.D. and M.A. in Philosophy from Boston College, both with highest honors. He has published dozens of academic papers and two books, and his work has earned awards and grants from the American Philosophical Association, the National Endowment for the Humanities, and the National Endowment for the Arts. He has lectured at Princeton, Columbia, and McGill Universities, and his research and commentary have been featured in The Guardian, BBC World, and Time Magazine.

Beyond academia, Dr. Purcell is recognized for his contributions to financial education, with over 61 million views across platforms for his writing and video content on investing and behavioral finance. His work integrates rigorous logical frameworks with practical investment insights, reflecting a rare combination of philosophical depth and real-world application.